Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas
文献类型：期刊论文
| 作者 | Zhaohui Wang; Lili Li; Xianwei Su; Zifen Gao; Gopesh Srivastava; Paul G Murray; Richard Ambinder; Qian Tao |
| 刊名 | JOURNAL OF TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2012 |
| 英文摘要 | Background Inactivaion of tumor suppressor genes (TSGs) by promoter CpG methylation frequently occurs in tumorigenesis, even in the early stages, contributing to the initiation and progression of human cancers. Deleted in lung and esophageal cancer 1 (DLEC1), located at the 3p22-21.3 TSG cluster, has been identified frequently silenced by promoter CpG methylation in multiple carcinomas, however, no study has been performed for lymphomas yet. Methods We examined the expression of DLEC1 by semi-quantitative reverse transcription (RT)-PCR, and evaluated the promoter methylation of DLEC1 by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) in common lymphoma cell lines and tumors. Results Here we report that DLEC1 is readily expressed in normal lymphoid tissues including lymph nodes and PBMCs, but reduced or silenced in 70% (16/23) of non-Hodgkin and Hodgkin lymphoma cell lines, including 2/6 diffuse large B-cell (DLBCL), 1/2 peripheral T cell lymphomas, 5/5 Burkitt, 6/7 Hodgkin and 2/3 nasal killer (NK)/T-cell lymphoma cell lines. Promoter CpG methylation was frequently detected in 80% (20/25) of lymphoma cell lines and correlated with DLEC1 downregulation/silencing. Pharmacologic demethylation reversed DLEC1 expression in lymphoma cell lines along with concomitant promoter demethylation. DLEC1 methylation was also frequently detected in 32 out of 58 (55%) different types of lymphoma tissues, but not in normal lymph nodes. Furthermore, DLEC1 was specifically methylated in the sera of 3/13 (23%) Hodgkin lymphoma patients. Conclusions Thus, methylation-mediated silencing of DLEC1 plays an important role in multiple lymphomagenesis, and may serve as a non-invasive tumor marker for lymphoma diagnosis. |
| 收录类别 | SCI |
| 原文出处 | http://download.springer.com/static/pdf/699/art%253A10.1186%252F1479-5876-10-209.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2F1479-5876-10-209&token2=exp=1434978043~acl=%2Fstatic%2Fpdf%2F699%2Fart%25253A10.1186%25252F1479-5876-10-209.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1186%252F1479-5876-10-209*~hmac=1c3c1bf989320d4f4e51f7af6b07613955e7fde5eed73ebff65cb8190791109d |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/4290]  |
| 专题 | 深圳先进技术研究院_医药所 |
| 作者单位 | JOURNAL OF TRANSLATIONAL MEDICINE |
| 推荐引用方式 GB/T 7714 | Zhaohui Wang,Lili Li,Xianwei Su,et al. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas[J]. JOURNAL OF TRANSLATIONAL MEDICINE,2012. |
| APA | Zhaohui Wang.,Lili Li.,Xianwei Su.,Zifen Gao.,Gopesh Srivastava.,...&Qian Tao.(2012).Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.JOURNAL OF TRANSLATIONAL MEDICINE. |
| MLA | Zhaohui Wang,et al."Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas".JOURNAL OF TRANSLATIONAL MEDICINE (2012). |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。